AquaBounty Technologies (NASDAQ:AQB) versus Tyra Biosciences (NASDAQ:TYRA) Head to Head Analysis

AquaBounty Technologies (NASDAQ:AQB) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional & Insider Ownership

8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 2.2% of AquaBounty Technologies shares are held by insiders. Comparatively, 15.2% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

AquaBounty Technologies has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for AquaBounty Technologies and Tyra Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1	0	0	0	1.00
Tyra Biosciences	1	0	5	1	2.86

Tyra Biosciences has a consensus target price of $33.17, suggesting a potential upside of 27.76%. Given Tyra Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than AquaBounty Technologies.

Earnings and Valuation

This table compares AquaBounty Technologies and Tyra Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	N/A	N/A	-$149.19 million	($0.83)	-1.23
Tyra Biosciences	N/A	N/A	-$86.48 million	($1.87)	-13.88

Tyra Biosciences is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AquaBounty Technologies and Tyra Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-553.11%	-283.83%
Tyra Biosciences	N/A	-35.76%	-33.58%

Summary

Tyra Biosciences beats AquaBounty Technologies on 9 of the 12 factors compared between the two stocks.

About AquaBounty Technologies

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.